Opinion|Videos|February 3, 2025
Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks
Panelists discuss monitoring parameters when treating patients with polycythemia vera (PV), including what to assess, typical outcomes, and when treatment should be switched due to ineffectiveness. Dr Kuykendall to Dr Gangat: Panelists explore the risk of PV progression/transformation, risk factors for progression, and how the data influence patient care and treatment choices in practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are your monitoring parameters when treating patients for PV?
- What do you assess, and what are typical outcomes for patients with PV patients?
- At what point is treatment determined to be ineffective, and should thus needing to be switched?
- Please discuss the risk of PV progression/transformation.
- What are risk factors for PV progression?
- How does the data impact patient care and treatment choices in your practice?
Advertisement
Related to this article
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.
The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.
Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.
Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5